Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jin Huh

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
The Journal of Clinical Investigation|June 3, 2011
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumorsLauren L C Marotta, Vanessa Almendro, Andriy Marusyk, et al.
Cancer Discovery|June 28, 2017
Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma TransitionCarlos R Gil Del Alcazar, Sung Jin Huh, Muhammad B Ekram, et al.
Journal of the American Chemical Society|March 19, 2021
Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic ToxicitiesFarrukh Vohidov, Jannik N Andersen, Kyriakos D Economides, et al.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
Nature Communications|September 15, 2019
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situLina Ding, Ying Su, Anne Fassl, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
The Journal of Clinical Investigation|June 3, 2011
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumorsLauren L C Marotta, Vanessa Almendro, Andriy Marusyk, et al.
Cancer Discovery|June 28, 2017
Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma TransitionCarlos R Gil Del Alcazar, Sung Jin Huh, Muhammad B Ekram, et al.
Journal of the American Chemical Society|March 19, 2021
Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic ToxicitiesFarrukh Vohidov, Jannik N Andersen, Kyriakos D Economides, et al.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
Nature Communications|September 15, 2019
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situLina Ding, Ying Su, Anne Fassl, et al.
Pageof 11